title: Sickness absence and return to work rates in women with breast cancer.
abstract: OBJECTIVE
  Most women are diagnosed with breast cancer when they are of working age. How long are breast cancer patients absent? How many of them return to work?
  
  
  METHODS
  ArboNed Occupational Health Services documents sickness absence data of 1 million workers of whom 40% were women. Between 2001 and 2005, 2,259 women had 2,361 episodes of sickness absence due to breast cancer. These absence episodes were followed for 2 years using Kaplan-Meier analysis.
  
  
  RESULTS
  The mean +/- standard error of mean duration of absence due to breast cancer was 349 +/- 5 days. Thirty-seven percent of absences lasted longer than one year and 12% of absences lasted longer than 2 years particularly in women aged 25-34 years.
  
  
  CONCLUSIONS
  The mean duration of sickness absence due to breast cancer was nearly a year, but most women returned to work. The results of the study can be used as a reference for return to work of women following breast cancer.
authors.affiliation: Department of Health Sciences, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. corne.roelen@arboned.nl
authors.forename: Corné A M
authors.initials: CA
authors.lastname: Roelen
authors.forename: Petra C
authors.initials: PC
authors.lastname: Koopmans
authors.forename: Jan H
authors.initials: JH
authors.lastname: de Graaf
authors.forename: Fulya
authors.initials: F
authors.lastname: Balak
authors.forename: Johan W
authors.initials: JW
authors.lastname: Groothoff
mesh_terms: D000041:Absenteeism; D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000534:rehabilitation*; D003289:Convalescence; D005260:Female; D006801:Humans; D008875:Middle Aged; D009426:Netherlands; D009786:Occupational Health Services; D012042:Registries; D018582:Sick Leave / Q000706:statistics & numerical data*; D016019:Survival Analysis; D013997:Time Factors; D055815:Young Adult
references.citation: J Cancer Surviv. 2007 Jun;1(2):129-36
references.pmid: 18648953
references.citation: AAOHN J. 2007 Jul;55(7):290-5
references.pmid: 17665826
references.citation: Clin J Pain. 2003 Mar-Apr;19(2):87-96
references.pmid: 12616178
references.citation: Br J Psychiatry. 2004 Mar;184:240-6
references.pmid: 14990522
references.citation: J Natl Cancer Inst. 2004 Dec 15;96(24):1813-22
references.pmid: 15601637
references.citation: Soc Sci Med. 1993 Aug;37(3):295-304
references.pmid: 8356479
references.citation: J Clin Oncol. 2006 Jan 20;24(3):345-53
references.pmid: 16421415
references.citation: Rheumatology (Oxford). 2003 Mar;42(3):435-41
references.pmid: 12626793
references.citation: Health Serv Res. 2002 Oct;37(5):1309-28
references.pmid: 12479498
references.citation: Psychooncology. 2002 Mar-Apr;11(2):124-31
references.pmid: 11921328
references.citation: J Occup Med. 1992 Nov;34(11):1084-9
references.pmid: 1432298
references.citation: Cancer. 2005 Mar 15;103(6):1292-301
references.pmid: 15700265
references.citation: Scand J Public Health Suppl. 2004;63:222-55
references.pmid: 15513660
references.citation: CMAJ. 2005 Sep 27;173(7):765-71
references.pmid: 16186583
references.citation: PLoS Med. 2006 Mar;3(3):e88
references.pmid: 16563039
references.citation: J Natl Cancer Inst Monogr. 1994;(16):35-42
references.pmid: 7999467
references.citation: Occup Environ Med. 2003 Jun;60(6):429-37
references.pmid: 12771395
references.citation: Psychooncology. 2004 Mar;13(3):147-60
references.pmid: 15022150
references.citation: N Engl J Med. 2002 Dec 19;347(25):1999-2009
references.pmid: 12490681